Hormonal
Oral semaglutide significantly reduces blood glucose levels (HbA1c) and improves glycemic control in patients with Type 2 Diabetes compared to placebo and other active comparators.
If you have Type 2 Diabetes and struggle with injections, oral semaglutide is a proven option. Start with a low dose (3mg daily) for a month, then increase to 7mg or 14mg based on your blood sugar needs. It effectively lowers HbA1c levels and helps manage cardiovascular risk.
The report concluded that the patients with type II Diabetes mellitus had more optimal glucose level as tested by glycosylated hemoglobin test (HbA1C) in comparison with the Placebo.
Why this rating
Based on multiple Phase III PIONEER trials (PIONEER-1, 3, 4, 7, 8, 9, 10) comparing semaglutide to placebo and other drugs.
Source
A Systematic Review of Oral Semaglutide for Type II Diabetes
A.Suseendra kumar et al. · International Journal of Pharmaceutical Sciences Review and Research · 2021
DOI 10.47583/ijpsrr.2021.v68i01.031
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →